Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

OPGx-RDH12

Gene therapy · developed by Opus Genetics

Phase 1/2 Most advanced trial
IRD Developer
1 Registered trials

What is OPGx-RDH12?

OPGx-RDH12 is a gene therapy carrying the RDH12 gene, intended to deliver a functional copy of this retinol dehydrogenase to retinal cells. It is studied in Leber congenital amaurosis, an inherited retinal disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Gene therapy
Therapy area
Ophthalmology
Developer
Opus Genetics, Inc (IRD)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07681778 Phase 1/2 Leber Congenital Amaurosis Not yet recruiting IRD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Leber Congenital AmaurosisLeber Congenital Amaurosis (LCA)

More from Opus Genetics

AAV8.hLCA5 Phase 1/2 Erenapurstat Phase 2

Follow IRD, the company behind OPGx-RDH12

See IRD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IRD catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.